Asep Medical has secured patent approval in the US for its AI-based sepsis diagnostic technology, SepsetER.

The patent for the technology, together with patents awarded in Europe and Australia in November 2022, represents nearly 400 million people.

The patent has been licenced exclusively to Asep’s subsidiary Sepset Biosciences. It validates the AI-based approach to sepsis diagnosis, a disease which is said to cause more than 11 million deaths annually across the globe.

SepsetER is designed to help physicians quickly predict the severity of the disease and initiate urgent patient treatment.

The blood-based gene expression assay, which allows earlier risk assessment, senses the dysfunctional immune response underlying sepsis in patients.

Asep CEO Dr Robert Hancock said: “Patents are the lifeblood of biotechnology companies like ours. This new patent in the US once again validates the novelty of our technology in major markets, which now represents over 700 million people.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The company is considering formal clinical 510(k) studies in the US for this sepsis diagnostic technology.

Asep has validated and refined the SepsetER signature in more than 700 patients with Sepsis and Covid-19 to date. It is now planning duplication in a formal trial.

The test provides results in approximately 60-90 minutes, unlike current diagnostic tools that deliver results after roughly eight to 36 hours, which leads to delay in the treatment initiation.